Aller au contenu

Publications scientifiques

  • article Das A, Florence T, Rodrigues CR, Ambros B, Singh J, Fonge H, Aulakh GK

    Development of angiostatin based radiopharmaceutical as a sensitive tool for detection of ATP synthase during acute vascular damage

    Nucl Med Biol 156-157 2026.

    DOI PUBMED
  • article Njotu FN, Garcia MD, Nwangele E, Babeker H, Pougoue Ketchemen J, Doroudi A, Price EW, Gordon JR, Uppalapati M, Fonge H

    Efficacy of a site-specific anti-Nectin-4 antibody-drug conjugate against Nectin-4-positive triple-negative breast cancer models

    Int J Pharm 698 2026.

    DOI PUBMED
  • article Pougoue Ketchemen J, Monzer A, Njotu FN, Babeker H, Tikum AF, Nwangele E, Henning N, Hassani N, Ngong AF, Doroudi A, Fonge H

    Potency and safety of novel [225Ac]Ac-labeled pertuzumab-PEGylated emtansine drug conjugate against HER2-positive breast cancer

    Br J Cancer 2026.

    DOI PUBMED
  • article Tikum AF, Fon DA, Njotu FN, Henning N, Nwangele E, Babeker H, Ketchemen JP, Doroudi A, Uppalapati M, Fonge H

    [225Ac]Ac-labeled matuzumab is an effective radioimmunotherapeutic against EGFR-positive triple negative breast cancer

    Breast Cancer Res 28 (1), 2026.

    DOI PUBMED
  • article Pougoue Ketchemen J, Ahenkorah S, Nwangele E, Malaza SSP, Ooms M, Cardinaels T, Leekens S, Cleeren F, Fonge H

    Preclinical characterization of 3p-C-DEPA-NCS and 3p-C-DEPA-TFP-PEG4 as potential Actinium-225 bifunctional chelators using DOTA-NCS and macropa-NCS as benchmarks

    EJNMMI Radiopharm Chem 10 (1), 2025.

    DOI PUBMED
  • article Khosravifarsani M, Njotu FN, Fon DA, Fonge H

    Maximizing therapeutic potential and safety: Exploring multi/dual-payload antibody conjugates as cancer theranostics

    Adv Drug Deliv Rev 222 2025.

    DOI PUBMED
  • article Bednova O, Pougoue Ketchemen J, Mslati H, Barok M, Joensuu H, Zeytuni N, Gentile F, Sanche L, Fonge H, Leyton JV

    Integrating Biochemical and Computational Approaches Reveal Structural Insights in Trastuzumab scFv-Fc Antibody Engineering

    Biomolecules 15 (5), 2025.

    DOI PUBMED
  • article Babeker H, Njotu FN, Pougoue Ketchemen J, Monzer A, Tikum AF, Doroudi A, Nwangele E, Uppalapati M, Fonge H

    225Ac/89Zr-Labeled N4MU01 Radioimmunoconjugates as Theranostics Against Nectin-4-Positive Triple-Negative Breast Cancer

    J Nucl Med 66 (4), 2025.

    DOI PUBMED
  • article Tikum AF, Henning NW, Pougoue Ketchemen J, Doroudi A, Babeker H, Njotu FN, Nwangele E, Monzer A, Gray B, Torlakovic E, Uppalapati M, Fonge H

    An Anti-EGFR Antibody-Drug Radioconjugate Labeled with Actinium-225 Elicits Durable Antitumor Responses in KRAS- and BRAF-Mutant Colorectal Cancer

    Cancer Res 85 (11), 2025.

    DOI PUBMED
  • article Pougoue Ketchemen J, Njotu FN, Babeker H, Monzer A, Nwangele E, Tikum AF, Henning N, Hassani N, Frye S, Perron R, Byrne C, Didychuk C, Qi Q, Bannister L, Doroudi A, Fonge H

    Complete Remissions of HER2-Positive Trastuzumab-Resistant Xenografts Using a Potent [225Ac]Ac-Labeled Anti-HER2 Antibody-Drug Radioconjugate

    Clin Cancer Res 31 (4), 2025.

    DOI PUBMED
  • article Njotu FN, Pougoue Ketchemen J, Babeker H, Henning N, Tikum AF, Nwangele E, Monzer A, Hassani N, Gray BD, Pak KY, Torlakovic EE, Uppalapati M, Fonge H

    Preclinical safety and effectiveness of a long-acting somatostatin analogue [225Ac]Ac-EBTATE against small cell lung cancer and pancreatic neuroendocrine tumors

    Eur J Nucl Med Mol Imaging 52 (4), 2025.

    DOI PUBMED
  • article Tikum AF, Ketchemen JP, Doroudi A, Nambisan AK, Babeker H, Njotu FN, Fonge H

    Effectiveness of 225Ac-Labeled Anti-EGFR Radioimmunoconjugate in EGFR-Positive Kirsten Rat Sarcoma Viral Oncogene and BRAF Mutant Colorectal Cancer Models

    J Nucl Med 2024.

    DOI PUBMED